NEW YORK (GenomeWeb) – Intrexon has entered into a definitive agreement to buy bovine genetics firm Trans Ova Genetics for up to $110 million. Shareholders will receive $60 million in upfront cash, $30 million in Intrexon stock, and up to $20 million in deferred payments. Trans Ova will become a wholly owned subsidiary of Intrexon upon completion of the transaction, which is expected in the third quarter, and will be led by David Faber, currently Trans Ova's president, and his management team.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.